170 results
DEFA14A
ZVRA
Zevra Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
7:49am
acquisition in mid-November 2023, we have made meaningful progress towards ensuring that people who suffer from certain urea cycle disorders (UCDs) have access … that reimbursements from the arimoclomol expanded access program in France will continue to provide approximately $2.1 million in net revenue per
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
28 Mar 24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
4:35pm
and Chief Executive Officer of Zevra. “As we look to 2024, our strategic priorities are clear; first, successfully launch OLPRUVA® and ensure access … team with decades of experience in rare diseases. The team includes Rare Disease Sales Specialists, Marketers, Patient Services and Market Access
8-K
EX-99.1
dlkpc
4 Mar 24
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
8:24am
8-K
EX-3.1
gxdu50w56d3 mzgw6
28 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:29pm
8-K/A
EX-99.3
l1xfjt91
5 Feb 24
Financial Statements and Exhibits
12:00am
8-K
EX-99.1
yr0o70vjven
8 Jan 24
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
8:03am
8-K
EX-99.1
4oc8to4w6r jsx
27 Dec 23
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
7:48am
8-K
EX-99.1
le6yl4
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-10.1
m7rc6w
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-99.2
i4mzyp7qkmr 4a
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
EX-99.1
wcwfkyjq
7 Nov 23
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial
7:25am
425
EX-99.1
042nwjqvzl8q9hu
30 Oct 23
Business combination disclosure
4:42pm
8-K
EX-99.1
m2bgy d6x
30 Oct 23
Other Events
8:25am
8-K
EX-10.1
5yankv4n62ilo9w
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
424B3
cnzsona3a 5i895
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
97ty 04sdobben
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm